Long Read Sequencing Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.36 Billion |
| Market Size (2030) | USD 3.87 Billion |
| CAGR (2025 - 2030) | 23.32% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Long Read Sequencing Market Analysis
The Long Read Sequencing Market size is estimated at USD 1.36 billion in 2025, and is expected to reach USD 3.87 billion by 2030, at a CAGR of 23.32% during the forecast period (2025-2030).
Factors such as a surge in genetic disease prevalence and technological advancements in genomic research and precision medicine are projected to drive the long-read sequencing market. Furthermore, the expanding applications of long-read sequencing are anticipated to bolster market growth in the coming years. The declining costs associated with long-read sequencing are also broadening access to these technologies for a wider array of researchers and healthcare providers.
The rising prevalence of genetic disorders significantly fuels the growth of the long-read sequencing market. For instance, in March 2024, data published in Lancet Global Health indicated that around 300 million individuals worldwide are affected by rare diseases, with roughly 80% of these cases having a genetic origin. A September 2023 article from the National Institute of Health and Care Research estimated that about 3.5 million people in the UK have a rare disease. Given its capability to produce contiguous reads and provide a holistic view of the genome, long-read sequencing is increasingly favored for investigating these disorders. Thus, as genetic disorders become more prevalent, the demand for comprehensive genomic analysis rises, driving the market's expansion.
Moreover, advancements in genomic research and precision medicine fuel the growth of the long-read sequencing market. By offering enhanced accuracy and the capability to capture intricate genomic regions, long-read sequencing technologies have revolutionized genomic research, positioning themselves as essential tools for precision medicine. Notable examples include Pacific Biosciences' Single Molecule Real-Time (SMRT) sequencing and Oxford Nanopore's nanopore sequencing. With their extended read lengths, these technologies allow researchers to pinpoint structural variants, gene fusions, and epigenetic modifications with greater precision than traditional short-read methods.
Technological advancements, particularly in NGS, have reduced sequencing costs and boosted throughput. This has paved the way for broader adoption of long-read sequencing in clinical research and diagnostics. For instance, data from Illumina reveals a staggering 96% drop in average annual genome costs from 2013 to 2023, plummeting from USD 5,467 to just USD 200. Further pushing the envelope, Ultima Genomics, Inc. unveiled its UG 100 sequencer in February 2024, promising a groundbreaking cost of just USD 100 per genome. This leap, achieved through cutting-edge sequencing technologies and engineering, ensures both affordability and high accuracy. Such advancements democratize access to genomic research and promise to accelerate its pace.
Furthermore, the growing applications of long-read sequencing are propelling its market expansion. Its adoption is surging across various fields, including human genomics, cancer research, microbiology, and plant and animal genomics. For instance, in oncology, this technology aids in identifying new mutations driving cancer progression. A March 2023 study from the EMBL (European Molecular Biology Laboratory) underscored long-read sequencing's superiority over short-read methods in mutation detection. Using Oxford Nanopore's MinION device, EMBL researchers delved into a medulloblastoma, revealing a unique mutation pattern. With increasing R&D investments and expanding applications, the market is poised for substantial growth.
However, despite the optimistic outlook for the long-read sequencing market, challenges loom. High equipment and operational costs, coupled with the complexities of data analysis, could hinder the widespread adoption of these technologies.
Long Read Sequencing Market Trends
Nanopore Sequencing Segment is Expected to Hold a Major Market Share in the Long Read Sequencing Market
Nanopore sequencing will dominate the long-read sequencing market during the forecast period because of its real-time sequencing capabilities, extended read lengths, and portability. These attributes make it suitable for diverse applications, from in-depth genomic studies and field research to clinical diagnostics, fueling its rising adoption and market dominance. Additionally, its cost-effectiveness and enhanced accuracy render nanopore sequencing more accessible to both research and clinical labs. Thus, this technology's distinct advantages drive its increasing market adoption.
Furthermore, companies are partnering with research institutions and biopharma entities to develop innovative applications, reagents, and sequencing workflows, expanding the technology's reach and capabilities. For instance, in September 2024, MGI Tech Co., Ltd. introduced its CycloneSEQ-WT02 and CycloneSEQ-WY01 nanopore sequencing products. This introduction bolsters the long-read sequencing market by delivering superior accuracy and throughput, further promoting adoption in genomics research and clinical applications. In another instance, in May 2024, Oxford Nanopore Technologies partnered with Twist Bioscience to unveil a new Pharmacogenomics (PGx) Beta Programme. This initiative merges Twist's NGS target enrichment technology with Oxford Nanopore's sequencing platform, pushing the boundaries of personalized medicine. Such endeavors are set to propel market advancements, significantly amplifying the significance of nanopore sequencing in personalized medicine.
Additionally, the rising incidence of hemophilia in children is spurring the demand for sophisticated genomic tools like nanopore sequencing, which offers deeper insights into intricate genetic disorders. Data from the National Organization for Rare Disorders (NORD) in November 2023 reveals that Hemophilia A impacts roughly 1 in 5,000 newborn males, with 60% presenting the severe variant. Hemophilia, stemming from mutations in the F8 or F9 genes, necessitates precise genetic variant identification—a task made difficult by conventional short-read sequencing. With its capability to decipher lengthy DNA sequences, nanopore sequencing facilitates intricate genomic region mapping, aiding clinicians in identifying structural variations and crafting targeted therapies. Consequently, the rising prevalence of hemophilia underscores the demand for advanced sequencing technologies like nanopore sequencing, which ensure enhanced clinical outcomes and informed genetic counseling.
North America is Expected to Dominate the Long Read Sequencing Market
North America is set to dominate the long-read sequencing market, propelled by key drivers like the concentration of leading biotechnology firms, increased investments in genomics research, and a robust healthcare framework. The growing embrace of advanced sequencing technologies in both research and clinical settings further fuels this market expansion. The United States, in particular, emerges as a frontrunner in long-read sequencing advancements, with industry stalwarts such as Pacific Biosciences and Oxford Nanopore Technologies leading the charge in technological innovations and product launches.
Moreover, the rising prevalence of rare genetic disorders and chronic diseases in North America amplifies the demand for comprehensive genomic analyses. For example, data from the U.S. FDA in December 2022 highlighted that approximately 30 million individuals in the U.S. are grappling with around 7,000 rare diseases. Conditions like cystic fibrosis, Huntington’s disease, and Duchenne muscular dystrophy necessitate precise genetic insights for accurate diagnosis and treatment planning. The American Lung Association reported in June 2024 that roughly 30,000 individuals in the U.S. have cystic fibrosis. This disease prevalence underscores the need for advanced genomic solutions to unravel genetic mutations and disease mechanisms, propelling market growth.
Moreover, increased funding from both governmental bodies and private entities in genomics research and precision medicine is boosting the adoption of long-read sequencing in the region. For instance, a February 2024 article from the NIH (National Institute of Health) highlighted a USD 3.1 billion research initiative that unveiled over 275 million previously undocumented genetic variants from nearly 250,000 participants in the NIH’s All of Us Research Program. Notably, around 4 million of these newly identified variants are situated in areas potentially associated with disease risk.
Given these factors, including substantial R&D investments, a rising rate of genetic disorders, and the presence of industry leaders, North America is poised for continued growth in the long-read sequencing market.
Long Read Sequencing Industry Overview
The long read sequencing market is moderately consolidated in nature due to the presence of few major companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known. Major players include Hoffmann-La Roche Ltd., Illumina, Inc., MicrobesNG, Novogene Co., Ltd., Oxford Nanopore Technologies plc., PacBio, among others.
Long Read Sequencing Market Leaders
-
Illumina, Inc.
-
F. Hoffmann-La Roche Ltd.
-
PacBio
-
Oxford Nanopore Technologies plc.
-
Agilent Technologies, Inc.
- *Disclaimer: Major Players sorted in no particular order
Long Read Sequencing Market News
- July 2024: Oxford Nanopore Technologies and Plasmidsaurus strategically collaborated to advance plasmid sequencing and co-develop new applications, including microbial and gene therapy, with nanopore technology. Oxford Nanopore's long-read sequencing technology enables the reading of GC-rich or repetitive DNA, compared to traditional plasmid sequencing methods, which are limited by short read lengths. Thus, the collaboration aims to bolster the long-read sequencing market by broadening its applicability across various genomic domains.
- September 2023: PacBio collaborated with automation partners Hamilton, Integra, Revvity, and Tecan to develop comprehensive automated library preparation solutions. These protocols are designed for sample preparation on the Revio, Sequel II, and Sequel IIe systems. PacBio's collaboration with automation partners to develop comprehensive automated library preparation solutions is expected to drive long-read sequencing market growth by reducing costs, ensuring consistent results, and increasing sequencing throughput.
- March 2023: Illumina Inc. launched its cutting-edge, long-read human whole-genome sequencing (WGS) assay, Illumina Complete Long Read Prep, Human. The product is based on its novel Illumina Complete Long Read technology and is designed to seamlessly integrate with the Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. Users can now access long- and short-read data using the same Illumina instrument.
Long Read Sequencing Industry Segmentation
As per the report's scope, long-read sequencing is a cutting-edge genomic technology that produces long, contiguous reads of DNA or RNA sequences, often spanning thousands to millions of base pairs. It provides a comprehensive view of the genome and spans repetitive regions, structural variations, and complex genomic areas.
The long read sequencing market is segmented into product, technology, workflow, application, end user and geography. By product, the market is segmented into instruments, consumables, and services. Based on technology, the market is segmented into single molecule real-time (SMRT) sequencing, nanopore sequencing and synthetic long read sequencing. The market is segmented by workflow into pre-sequencing, sequencing, and data analysis. The market is segmented by application into whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene sequencing, metagenomics, epigenetics, and others. By end-user, the market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. The market sizing and forecasts were made for each segment based on value (USD).
| By Product | Instruments | ||
| Consumables | |||
| Services | |||
| By Technology | Single Molecule Real-time (SMRT) Sequencing | ||
| Nanopore Sequencing | |||
| Synthetic Long Read Sequencing | |||
| By Workflow | Pre-sequencing | ||
| Sequencing | |||
| Data Analysis | |||
| By Application | Whole Genome Sequencing (WGS) | ||
| Whole Exome Sequencing (WES) | |||
| Target Gene Sequencing | |||
| Metagenomics | |||
| Epigenetics | |||
| Others | |||
| By End-User | Academic & Research Institutes | ||
| Pharmaceutical & Biotechnology Companies | |||
| Hospitals & Clinics | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Long Read Sequencing Market Research FAQs
How big is the Long Read Sequencing Market?
The Long Read Sequencing Market size is expected to reach USD 1.36 billion in 2025 and grow at a CAGR of 23.32% to reach USD 3.87 billion by 2030.
What is the current Long Read Sequencing Market size?
In 2025, the Long Read Sequencing Market size is expected to reach USD 1.36 billion.
Who are the key players in Long Read Sequencing Market?
Illumina, Inc., F. Hoffmann-La Roche Ltd., PacBio, Oxford Nanopore Technologies plc. and Agilent Technologies, Inc. are the major companies operating in the Long Read Sequencing Market.
Which is the fastest growing region in Long Read Sequencing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Long Read Sequencing Market?
In 2025, the North America accounts for the largest market share in Long Read Sequencing Market.
What years does this Long Read Sequencing Market cover, and what was the market size in 2024?
In 2024, the Long Read Sequencing Market size was estimated at USD 1.04 billion. The report covers the Long Read Sequencing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Long Read Sequencing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Long Read Sequencing Industry Report
Statistics for the 2025 Long Read Sequencing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Long Read Sequencing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
